Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Transcriptomic landscape of circulating mononuclear phagocytes in Langerhans cell histiocytosis at the single-cell level

Blood (2021) 138 (14): 1237–1248.

https://doi.org/10.1182/blood.2020009064

Published: 2021

Includes: Supplemental data

Journal Articles

Determining Resistance Mechanisms in BRAF- mutated Multiple Myeloma

Johannes M. Waldschmidt, MD, Jake A. Kloeber, Tushara Vijaykumar, Antonis Kokkalis, PhD MSc, Praveen Anand, PhD, Sayalee Potdar, Julia Frede, PhD MPhil, Monica S. Nair, Valeriya Dimitrova, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Andrew J. Yee, MD, Noopur S. Raje, MD, Birgit Knoechel, MD PhD, Jens G. Lohr, MD PhD

Blood (2019) 134 (Supplement_1): 316.

https://doi.org/10.1182/blood-2019-130313

Published: 2019

Journal Articles

A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera

Jason Gotlib, MD MS, Nashat Gabrail, MD, Casey L. O'Connell, MD, Regina Garcia-Delgado, MD, Timothy Sbardellati, Wayne M. Rothbaum, Jesse McGreivy, Claire N Harrison, Professor, Jean-Jacques Kiladjian, MD PhD

Blood (2019) 134 (Supplement_1): 4168.

https://doi.org/10.1182/blood-2019-123546

Published: 2019

Journal Articles

Low-Dose BRAF-Inhibitors in the Treatment of Histiocytic Disorders with the BRAF-V600E Mutation

Gordon Ruan, MD, Gaurav Goyal, MBBS, Jithma P. Abeykoon, MD, N. Nora Bennani, MD, Karen Rech, MD, Jason Young, MD, Mithun Vinod Shah, MD PhD, Ronald S. Go, MD

Blood (2019) 134 (Supplement_1): 5895.

https://doi.org/10.1182/blood-2019-124891

Published: 2019

Journal Articles

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Regina Garcia-Delgado, MD, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, László Rejtő, Eric Jourdan, MD, Haifa Kathrin Al-Ali, MD, Andrzej Pluta, MD, Marek Hus, MD PhD, Joanne Ewing, PhDBMBS BSc FRPATH, Irum Khan, MD, Holger Hebart, Philipp J. Jost, MD, Sebastian Grosicki, MD PhD, Wayne M. Rothbaum, Jesse McGreivy, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 2945.

https://doi.org/10.1182/blood-2019-123836

Published: 2019

Journal Articles

Down-Regulation of CD25 Antigen in Hairy Cell Leukemia Patients after Treatment

Mirela Anghelina, Narendranath Epperla, MD MS, Kerry A. Rogers, MD, Ling Guo, MD, Qiuhong Zhao, MS, James S. Blachly, MD, David M. Lucas, PhD, Christopher C. Oakes, Gerard Lozanski, MD, Michael R. Grever, MD, Leslie A. Andritsos, MD

Blood (2018) 132 (Supplement 1): 4143.

https://doi.org/10.1182/blood-2018-99-120043

Published: 2018

Journal Articles

High-Risk Langerhans Cell Histiocytosis in Infants Exhibits Malignant Features in a Xenograft Model but Responds Durably to Targeted Therapy

Lynn Lee, MD, Mary Christa Krupski, DO, MPH, Jason Clark, MS, Robert B. Lorsbach, MD PhD, Michael Grimley, MD, Matthew Burwinkel, Adam S. Nelson, MBBS, Ashish R Kumar, MD PhD

Blood (2018) 132 (Supplement 1): 4323.

https://doi.org/10.1182/blood-2018-99-119383

Published: 2018

Journal Articles

Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL)

Robert J. Kreitman, MD, Philippe Moreau, Martin Hutchings, MD, Anas Gazzah, MD, Jean-Yves Blay, MD PhD, Zev A. Wainberg, MD, Alexander Stein, MD, Sascha Dietrich, MD, Maja J.A. de Jonge, MD, Wolfgang Willenbacher, MD, Jacques De Greve, MD, Evgeny Arons, PhD, Farhad Ravandi, MD, Fatima Rangwala, Paul Burgess, Bijoyesh Mookerjee, Vivek Subbiah, MD

Blood (2018) 132 (Supplement 1): 391.

https://doi.org/10.1182/blood-2018-99-113135

Published: 2018

Journal Articles

CIC-Mutation As a Potential Molecular Mechanism of Acquired Resistance to Combined BRAF/MEK Inhibition in CNS Multiple Myeloma

Matteo Claudio Da Via', MD, Antonio Giovanni Solimando, MD, Andoni Garitano-Trojaola, PhD, Santiago Barrio, PhD, Nadine Rodhes, Susanne Strifler, MD, Eva Teufel, Constantin Lapa, MD, Hermann Einsele, MD, Andreas Beilhack, MD, K. Martin Kortüm, MD

Blood (2018) 132 (Supplement 1): 3181.

https://doi.org/10.1182/blood-2018-99-117203

Published: 2018

Journal Articles

MET-PET and NGS Targeted Sequencing Guides Precision Medicine in a CNS Relapsed MM Patient

Matteo Da Via', MD, Susanne Strifler, MD, Santiago Barrio Garcia, PhD, Andoni Garitano Trojaola, PhD, Eva Teufel, Silvia Nerreter, A. Keith Stewart, MBChB, MBA, Andreas Rosenwald, Anke Heidemeier, MD, Constantin Lapa, MD, Hermann Einsele, K. Martin Kortüm, MD

Blood (2017) 130 (Supplement 1): 5361.

https://doi.org/10.1182/blood.V130.Suppl_1.5361.5361

Published: 2017

Journal Articles

Anti-CD123 CAR T-Cell Therapy for the Treatment of Myelodysplastic Syndrome

Wei Zhang, MS, Brett M Stevens, PhDBS, Elizabeth Elizabeth Budde, MD PhD, Stephen J. Forman, MD FACP, Craig T. Jordan, PhD, Enkhtsetseg Purev, MD PhD

Blood (2017) 130 (Supplement 1): 1917.

https://doi.org/10.1182/blood.V130.Suppl_1.1917.1917

Published: 2017

Journal Articles

Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations

Thierry M. Nordmann, Freimut D. Juengling, Mike Recher, Christoph T. Berger, Daniel Kalbermatten, Andreas Wicki, Aino Paasinen-Sohns, Gieri Cathomas, Alexandar Tzankov, Thomas Daikeler

Blood (2017) 129 (7): 879–882.

https://doi.org/10.1182/blood-2016-09-740217

Published: 2017

Journal Articles

Real-Time Genomic Profiling Identifies Novel Mutations and Improved Therapy for Histiocytoses

Lynn Lee, MD, Anjelika Gasilina, Jayeeta Roychoudhury, PhD, Jason Clark, Francis X McCormack, MD, Joseph Gerald Pressey, MD, Robert B. Lorsbach, MD PhD, Siraj M Ali, MD PhD, Mark Bailey, MSc, Philip Stevens, PhD, Jeffrey S Ross, MD, Vincent A. Miller, MD, Nicolas Nassar, PhD, Ashish R Kumar, MBBS, PhD

Blood (2016) 128 (22): 2723.

https://doi.org/10.1182/blood.V128.22.2723.2723

Published: 2016

Journal Articles

Dramatic transient improvement of metastatic BRAF V600E -mutated Langerhans cell sarcoma under treatment with dabrafenib

Samia Mourah, Gwenaël Lorillon, Véronique Meignin, Laetitia Vercellino, Constance de Margerie-Mellon, Cécile Pages, Lauriane Goldwirt, Alexandre How-Kit, Jorg Tost, Céleste Lebbe, Abdellatif Tazi

Blood (2015) 126 (24): 2649–2652.

https://doi.org/10.1182/blood-2015-06-650036

Published: 2015

Includes: Supplemental data

Journal Articles

Constitutive Vs. Stroma-Induced Kinase Dependencies in Myeloma Cells: Functional Mapping Using Small Molecule Inhibitors As Chemical Probes

Eugen Dhimolea, PhD, Emily King, Michal Sheffer, PhD, Yiguo Hu, MDPhD, Pallavi P. Awate, Subhashis Sarkar, PhD, Geoffrey M. Matthews, PhD, Megan Murnane, Megan A. Bariteau, BSc, Blake T. Aftab, PhD, Constantine S Mitsiades, MD PhD

Blood (2015) 126 (23): 3709.

https://doi.org/10.1182/blood.V126.23.3709.3709

Published: 2015

Journal Articles

Cooperative Activity of BRAF F595L and Mutant HRAS in Histiocytic Sarcoma Provides New Insights into Oncogenic BRAF Signaling

Maximilian Kordes, Michael Röring, Christoph Heining, Sandra Braun, Barbara Hutter, Daniela Richter, Christina Geörg, Claudia Scholl, Wilfried Roth, Andreas Rosenwald, MD, Eva Geissinger, Christof von Kalle, Dirk Jäger, Benedikt Brors, Wilko Weichert, Carsten Grüllich, Hanno Glimm, Tilman Brummer, PhD, Stefan Fröhling

Blood (2015) 126 (23): 1631.

https://doi.org/10.1182/blood.V126.23.1631.1631

Published: 2015

Journal Articles

BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity

Valentina Pettirossi, Alessia Santi, Elisa Imperi, Guido Russo, Alessandra Pucciarini, Barbara Bigerna, Gianluca Schiavoni, Elisabetta Fortini, Ariele Spanhol-Rosseto, Paolo Sportoletti, Roberta Mannucci, Maria Paola Martelli, Ludger Klein-Hitpass, Brunangelo Falini, Enrico Tiacci

Blood (2015) 125 (8): 1207–1216.

https://doi.org/10.1182/blood-2014-10-603100

Published: 2015

Includes: Supplemental data

Journal Articles

Clinical Presentation, Diagnosis, Treatment, and Outcome of Patients with Erdheim-Chester Disease: The Mayo Clinic Experience

Mithun Vinod Shah, MD PhD, Timothy G Call, MD, Carl C. Hook, MD, Patrick B. Johnston, MD PhD, Louis Letendre, MD, Joseph P. Colgan, MD, Animesh Pardanani, MBBS, PhD, Bart L. Clarke, MD, Karen L Grogg, MD, Ronald S. Go, MD

Blood (2014) 124 (21): 1405.

https://doi.org/10.1182/blood.V124.21.1405.1405

Published: 2014

Journal Articles

Targeting The BRAF-MEK-ERK Pathway In Hairy Cell Leukemia

Valentina Pettirossi, Alessia Santi, Guido Russo, Alessandra Pucciarini, Barbara Bigerna, Elisabetta Fortini, Elisa Imperi, Roberta Mannucci, Ildo Nicoletti, Maria Paola Martelli, Enrico Tiacci, Brunangelo Falini

Blood (2013) 122 (21): 3064.

https://doi.org/10.1182/blood.V122.21.3064.3064

Published: 2013

Journal Articles

Co-Treatment Of Hairy Cell Leukemia and Melanoma With The BRAF Inhibitor Dabrafenib

Leslie A. Andritsos, MD, James S. Blachly, MD, Kari Kendra, M.D., Gerard Lozanski, M.D., Michael R. Grever, MD

Blood (2013) 122 (21): 5311.

https://doi.org/10.1182/blood.V122.21.5311.5311

Published: 2013

NARROW

Transcriptomic landscape of circulating mononuclear phagocytes in Langerhans cell histiocytosis at the single-cell level

Determining Resistance Mechanisms in BRAF- mutated Multiple Myeloma

A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera

Low-Dose BRAF-Inhibitors in the Treatment of Histiocytic Disorders with the BRAF-V600E Mutation

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Down-Regulation of CD25 Antigen in Hairy Cell Leukemia Patients after Treatment

High-Risk Langerhans Cell Histiocytosis in Infants Exhibits Malignant Features in a Xenograft Model but Responds Durably to Targeted Therapy

Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL)

CIC-Mutation As a Potential Molecular Mechanism of Acquired Resistance to Combined BRAF/MEK Inhibition in CNS Multiple Myeloma

MET-PET and NGS Targeted Sequencing Guides Precision Medicine in a CNS Relapsed MM Patient

Anti-CD123 CAR T-Cell Therapy for the Treatment of Myelodysplastic Syndrome

Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations

Real-Time Genomic Profiling Identifies Novel Mutations and Improved Therapy for Histiocytoses

Dramatic transient improvement of metastatic BRAF V600E -mutated Langerhans cell sarcoma under treatment with dabrafenib

Constitutive Vs. Stroma-Induced Kinase Dependencies in Myeloma Cells: Functional Mapping Using Small Molecule Inhibitors As Chemical Probes

Cooperative Activity of BRAF F595L and Mutant HRAS in Histiocytic Sarcoma Provides New Insights into Oncogenic BRAF Signaling

BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity

Clinical Presentation, Diagnosis, Treatment, and Outcome of Patients with Erdheim-Chester Disease: The Mayo Clinic Experience

Targeting The BRAF-MEK-ERK Pathway In Hairy Cell Leukemia

Co-Treatment Of Hairy Cell Leukemia and Melanoma With The BRAF Inhibitor Dabrafenib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only